At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,333 enrolled
Drug / intervention
Rosuvastatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN)
In Brief
A Phase 3 clinical trial evaluating Rosuvastatin and Atorvastatin for Coronary Atherosclerosis. Completed, enrolled 2,333 participants across 195 sites in 14 countries.
Detailed Summary
A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Atherosclerosis
CountriesArgentina, Australia, Belgium, Brazil, Canada, France, Hungary, Italy, Mexico, Netherlands, Poland, Russia, Spain, United States
CollaboratorsThe Cleveland Clinic
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedFeb 2008
Primary CompletionJun 2011
TodayJul 2026
First PostedFeb 21, 2008
Enrollment StartJan 1, 2008
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 18.4 years ago
Interventions
Rosuvastatindrug
capsule, oral, once daily
Atorvastatindrug
capsule, oral, one daily